Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study

dc.contributor.author	García-Portilla González, María Paz
dc.contributor.author	Benito Ruiz, A.
dc.contributor.author	Gómez Robina, F.
dc.contributor.author	García Dorado, M.
dc.contributor.author	López Rengel, P. M.
dc.date.accessioned	2022-10-25T11:09:22Z
dc.date.available	2022-10-25T11:09:22Z
dc.date.issued	2022
dc.identifier.citation	Expert Opinion on Pharmacotherapy, 23(5), p. 629-638 (2022); doi:10.1080/14656566.2021.2023496
dc.identifier.issn	1465-6566
dc.identifier.uri	http://hdl.handle.net/10651/64968
dc.format.extent	p. 629-638
dc.language.iso	eng
dc.relation.ispartof	Expert opinion on pharmacotherapy
dc.rights	© Informa UK Ltd, Taylor & Francis Group
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122502950&doi=10.1080%2f14656566.2021.2023496&partnerID=40&md5=84293f25591fc20331a418a9a8fe56c8
dc.title	Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study
dc.type	journal article
dc.identifier.doi	10.1080/14656566.2021.2023496
dc.relation.publisherversion	http://dx.doi.org/10.1080/14656566.2021.2023496

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.